William Blair assigns Outperform rating for BridgeBio with high growth potential
William Blair initiated coverage on BridgeBio, assigning an Outperform rating with a price target of $93.03 per share. Key drivers include upcoming product launches, particularly for Attruby, enhancing the firm's growth prospects and positioning against existing market leaders like Tafamidis.
View signal analysis